Online search behavior differs based on illness stage and condition info: Yahoo! survey

Share this article:

Consumers’ online health search behavior differs significantly based on their stage of illness and the condition they are seeking information on, a new study from Yahoo! found.


In a survey of 12,000 consumers, respondents were asked about their search behavior based on their stage in the illness cycle and their specific condition.


Among those surveyed, respondents fell into one of five categories:

*27% were undiagnosed.

*11% were diagnosed with an illness but not yet taking a prescription medication.

*24% were diagnosed and taking prescription medication with no plans to change.

*13% were diagnosed but considering switching their current medication.

*25% were diagnosed and considering stopping their current medication.


The Yahoo! survey found consumers in the undiagnosed stage are typically searching for information online because they are experiencing symptoms or are generally concerned about a condition and want to make lifestyle changes.


Additionally, the survey shows that in the diagnosis stage prior to taking a prescription drug, 50% of consumers rely heavily on search to determine if taking a medication is right for them.


The survey findings illustrate how important it is for pharma marketers to make sure general information and details about side effects are available on their branded and unbranded Web sites, according to Bonnie Becker, senior director of the pharmaceutical category for Yahoo! Search Marketing.


“Whether a consumer is looking online for information about a specific condition, learning about a certain stage of their illness, researching medication side effects, or finding ways to improve their health overall, search is the starting point of the online conversation,” Becker said. “In order to reach consumers and have maximum impact, marketers must not only include search in their overall marketing mix, but also tailor their messages to address consumers’ specific needs and concerns at critical phases during their search.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...